HEAL: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional)

US National Institutes of Health (NIH) grant open #FOR-DA-26-001

Summary

This NIH HEAL Initiative funding opportunity (R61/R33 phased award mechanism) supports research that translates findings from addiction epidemiology, prevention, treatment, and recovery science into real-world practice. The R61 phase is intended for milestone-driven developmental/feasibility work, with the R33 phase supporting expanded implementation upon successful completion. Clinical trials are optional under this announcement. The opportunity is currently forecasted and has not yet opened for applications.

What they want

Technical requirements

Phased R61/R33 award mechanism — R61 phase requires milestone-driven feasibility plan
Clinical trial component is optional but must be declared at time of application
Research must align with NIH HEAL Initiative priorities in addiction epidemiology, prevention, treatment, or recovery

How they evaluate

Scientific and technical merit (peer review)
Relevance to HEAL Initiative priorities
Feasibility of R61 milestones and transition to R33 phase
Qualifications of investigative team

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Opportunity is currently forecasted only — no full solicitation text available, so detailed requirements, deadlines, and evaluation criteria cannot be verified
R61/R33 phased mechanism introduces milestone-based go/no-go gates that may favor applicants with existing preliminary data in HEAL-aligned research areas

Market context

inferred from NAICS

Professional, Scientific & Technical Services

NAICS 541711

US market size: $2.0T
Typical award: $25K – $50M

Typical buyers

All federal civilianDoDStates

Commonly required

8(a)WOSBSDVOSBPE/PMP

Sector-level estimate — full code lookup not yet in catalog.

HEAL: Translating Addiction Epidemiology, …

$unknown

Onboard ↗